Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …

BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with
cancer. However, characteristics of the origins and molecular features of cell-free DNA are …

Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high
risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

In many areas of oncology, we lack sensitive tools to track low-burden disease. Although cell-
free DNA (cfDNA) shows promise in detecting cancer mutations, we found that the …

Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

Liver cancer is a global health challenge, causing a significant social-economic burden.
Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is …